Efficacy of Trametinib in Alleviating Cisplatin-Induced Acute Kidney Injury: Inhibition of Inflammation, Oxidative Stress, and Tubular Cell Death in a Mouse Model
Molecules · 2024
DOI: 10.3390/molecules29122881 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Joung Eun Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, School of Medicine, Daegu Catholic University, Daegu 42472, Republic of Korea. Hauptthemen laut MEDLINE: Cisplatin, Acute Kidney Injury, Pyridones, Oxidative Stress. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daegu Catholic University, National Research Foundation of Korea (NRF).
Abstract (Originalsprache)
Cisplatin, a platinum-based chemotherapeutic, is effective against various solid tumors, but its use is often limited by its nephrotoxic effects. This study evaluated the protective effects of trametinib, an FDA-approved selective inhibitor of mitogen-activated protein kinase kinase 1/2 (MEK1/2), against cisplatin-induced acute kidney injury (AKI) in mice. The experimental design included four groups, control, trametinib, cisplatin, and a combination of cisplatin and trametinib, each consisting of eight mice. Cisplatin was administered intraperitoneally at a dose of 20 mg/kg to induce kidney injury, while trametinib was administered via oral gavage at 3 mg/kg daily for three days. Assessments were conducted 72 h after cisplatin administration. Our results demonstrate that trametinib significantly reduces the phosphorylation of MEK1/2 and extracellular signal-regulated kinase 1/2 (ERK1/2), mitigated renal dysfunction, and ameliorated histopathological abnormalities. Additionally, trametinib significantly decreased macrophage infiltration and the expression of pro-inflammatory cytokines in the kidneys. It also lowered lipid peroxidation by-products, restored the reduced glutathione/oxidized glutathione ratio, and downregulated NADPH oxidase 4. Furthermore, trametinib significantly inhibited both apoptosis and necroptosis in the kidneys. In conclusion, our data underscore the potential of trametinib as a therapeutic agent for cisplatin-induced AKI, highlighting its role in reducing inflammation, oxidative stress, and tubular cell death.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Emergency Medicine, School of Medicine, Daegu Catholic University, Daegu 42472, Republic of Korea.
- Department of Immunology, School of Medicine, Daegu Catholic University, Daegu 42472, Republic of Korea.
ORCID-Profile: Joung Eun Lee, Jung-Yeon Kim, Jaechan Leem
Förderung
- Daegu Catholic University
- National Research Foundation of Korea (NRF)
Zitieren
APA
Lee, J. E., Kim, J. Y., & Leem, J. (2024). Efficacy of Trametinib in Alleviating Cisplatin-Induced Acute Kidney Injury: Inhibition of Inflammation, Oxidative Stress, and Tubular Cell Death in a Mouse Model. Molecules. https://doi.org/10.3390/molecules29122881
Vancouver
Lee JE, Kim JY, Leem J. Efficacy of Trametinib in Alleviating Cisplatin-Induced Acute Kidney Injury: Inhibition of Inflammation, Oxidative Stress, and Tubular Cell Death in a Mouse Model. Molecules. 2024. doi:10.3390/molecules29122881
BibTeX
@article{Lee2024,
author = {Lee, Joung Eun and Kim, Jung-Yeon and Leem, Jaechan},
title = {Efficacy of Trametinib in Alleviating Cisplatin-Induced Acute Kidney Injury: Inhibition of Inflammation, Oxidative Stress, and Tubular Cell Death in a Mouse Model},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29122881}
}
EUVIMED